Podcast: This Week in Managed Care&amp;mdash;New Voluntary Payment Model and Other Health News

As open enrollment begins November 1, 2025, millions are signing up under enhanced subsidies that are set to expire at the end of this year.

Age-Related Disparities in ADC Treatment Rates in Breast Cancer with Tabby Khan, MD

New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access

A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer.

Listen

Lawmaking | Image Credit: Polonio Video - stock.adobe.com

Managed Care Cast Presents: Leveraging Topical Therapies for Pediatric Atopic Dermatitis

PBM legislation is rising nationwide, which experts emphasize could increase costs and hinder patient care.

FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development

Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.

Listen

Marky Markary, MD, Robert F. Kennedy, Jr, and Mehmet Oz, MD

Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration

The FDA announced draft guidance to remove clinical efficacy studies for biosimilars and also issued the position that all biosimilars in the US should be interchangeable.

Healthcare.gov marketplace exchange | Image Credit: © Tada Images - stock.adobe.com

5 Consequences If ACA Premium Subsidies End in 2026

Premiums for coverage on the ACA marketplaces are set to jump by an average of 26% next year, even before the expiration of subsidies is factored in.

Related Content

As open enrollment begins November 1, 2025, millions are signing up under enhanced subsidies that are set to expire at the end of this year.

New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access

A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer.

Listen

Managed Care Cast Presents: Leveraging Topical Therapies for Pediatric Atopic Dermatitis

PBM legislation is rising nationwide, which experts emphasize could increase costs and hinder patient care.

FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development

Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.

Listen

Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration

The FDA announced draft guidance to remove clinical efficacy studies for biosimilars and also issued the position that all biosimilars in the US should be interchangeable.